Divi’s Labs Q2 PAT jumps 64% to ₹1,127 Cr

DIVISLAB Divi’s Laboratories Limited (DIVISLAB) reported Q2FY27 net profit of ₹1,127 Cr, up 64% YoY and 25% QoQ. Revenue rose 35% YoY and 19% QoQ to ₹3,676 ***** Divi’s Laboratories Limited (DIVISLAB) reported Q2FY27 net profit of ₹1,127 Cr, up 64% YoY and 25% QoQ. Revenue rose 35% YoY and 19% QoQ to ₹3,676 Cr Operating profit stood at ₹1,566 Cr, up 76% YoY and 25% QoQ. Operating margin expanded sharply to 42.6% from 32.7% YoY and 40.7% in the previous quarter. Other income was ₹94 Cr. EPS rose 64% YoY and 25% QoQ to ₹42.49. The strong performance was driven by higher revenues and significant margin expansion. The key triggers are the 64% YoY jump in PAT to ₹1,127 Cr and the expansion of operating margin to 42.6%, alongside 35% revenue growth. This marks a strong quarterly performance for the API and custom synthesis major. Peers such as Laurus Labs, Aurobindo Pharma and Cipla may face comparison on revenue growth and margin trends. Near-term prices could react positively to the robust profit growth and margin expansion. Risks include input cost pressure, regulatory hurdles in key export markets, or slower order inflows. Competitors listed: Laurus Labs, Aurobindo Pharma, Cipla. We have no financial interest in this news.